Pamela N. Munster, MD

Phone: 415-885-7810
UCSF Box: 1770
Email: pmunster@medicine.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
An Open-label, Multi-center, Extension Study of NKTR 102 in Subjects Previously Enrolled in NKTR-102 Studies Nektar Therapeutics United States Cancer/Oncology
Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment Nektar Therapeutics United States
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Cleave Biosciences, Inc United States Cancer/Oncology
Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumor Malignancies that have BRCA Mutations or Triple Negative Metastatic Breast Cancer QuantumLeap Healthcare Collaborative United States Cancer/Oncology
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Solid Tumors OncoMed Pharmaceuticals, Inc. United States Cancer/Oncology
A Phase 1 Study to Evaluate the Effect of NKTR-102 for Injection (etirinotecan pegol) on the QT/QTc Interval in Patients With Advanced or Metastatic Solid Tumors Nektar Therapeutics United States Cardiovascular Disease
Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies United States Cancer/Oncology, Drug and Diagnostics Development
CC# 159518 A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer MedImmune, Inc United States Cancer/Oncology, Drug and Diagnostics Development
Phase 1 Open Label, Multi-center Study to Assess the Safety, tolerability and Pharmacokinetics of Orally administered CUDC-907, an HDAC and PI3K Inhibitor in Subjects with Advanced/ Relapsed Solid Tumors Curis, Inc. United States Cancer/Oncology, Pharmacology and Drug Treatment
Project Sponsor Location(s) Topics Start End
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK) in Patients with Advanced Cancer Merck and Co., Inc. United States Cancer/Oncology
Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized 1gG1 Antibody in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors Genentech, Inc. United States Cancer/Oncology, Pharmacology and Drug Treatment
A Phase I Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients with Advanced Solid Tumors Novartis Pharma AG United States Cancer/Oncology
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma GlaxoSmithKline United States Cancer/Oncology
A Phase 1B, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors Novartis Oncology United States Cancer/Oncology, Women's Health
Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Malignancies That Are Refractory to All Standard United States Cancer/Oncology, Pharmacology and Drug Treatment
A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Novartis Oncology United States Cancer/Oncology
The role of HDAC2 in hormone therapy resistance NIH National Cancer Institute United States Cancer/Oncology
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer Novartis Oncology United States Cancer/Oncology, Women's Health